Anti-Human CD141 Azide Free
Product Specifications
- Catalogue N°
- 854.580.000 - 200µg / 200µl
854.580.005 - 500µg / 500µl - Target species
- Human
- Specificity
- Recognises thrombomodulin (TM), a 105 kDa protein
- Clone
- B-A35
- Application
- ELISA
- Flow Cytometry
- Hybridoma
- Myeloma X63/AG.8653 x Balb/c spleen cells
- Immunisation
- TF1 cell line
- Quantity
- 200µg or 500µg (Discovery Size also available please enquire)
- Isotype
- Mouse IgG1 Kappa light chain
- Format
- Phosphate-buffered saline. Sterile-filtered through 0.22 µm. Carrier and preservative free
- Storage
- Stable at +2-8°C for 12 months. For longer storage freeze aliquots.
- Synonym
- Thrombomodulin
Related products
- 854.581.010 - Anti-Human CD141 FITC Conjugated
- 854.583.020 - Anti-Human CD141 Unconjugated
- 879.720.001 - Anti-Human CD141 Capture Antibody
- 879.720.002 - Anti-Human CD141 Detection Antibody
- 850.720.048 - Human CD141 ELISA kit
- 851.690.001 - Human CD141 ELISA Set
- 853.850.000 - Anti-Human CD141 Azide Free
BACKGROUND
CD141 , also known as Thrombomodulin or BDC-A is an transmembrane protein expressed predominantly on the surface of vascular endothelial cells, but also on other cell types such as macrophages, monocytes, subpopulation of myeloid dendritic cells and keratinocytes. Thrombomodulin is a type 1 membrane glycoprotein of 74kDa consisting on a single chain with 6 Epidermal Growth Factor (EGF)-like domains critical for Thrombin and proteine C binding, and four other domains (an N-terminal C-type lectin domain, a highly glycosylated serine/threonine-rich domain, a transmembrane segment, and a short C-terminal cytoplasmic tail. It acts as an important component in the anti-coagulation and fibrinolysis system : cofactor for active thrombin, the thrombomodulin-thrombin complex activates protein C to degrade coagulation factors, inhibiting coagulation and fibrinolysis.
When vascular endothelial cells injury occurs, proteolytic cleavage release multiple fragments of thrombomodulin in circulation, so it represents a good marker for endothelial cell damage in pathologies such as cardiovascular disease, acute coronary syndrome, pulmonary thromboembolism or severe hemorrhage. Thrombomodulin has been described as an anticoagulant effect protein, and its therapeutical potential for preventing deep vein thrombosis and its use in the treatment of disseminated intravascular coagulation is under demonstrated in preliminary data.
More recently, other biological effects beyond anticoagulation have been demonstrated such as an anti-inflammatory , cell adhesion and proliferation regulation It is also demonstrated that thrombomodulin may be able to suppress the metastatic capacity of tumor cells, and hence have a protective role in many types of malignancies.
Version 7 - 06.19
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.